Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Squamous Cell Carcinoma of Head and Neck 1Precancerous Conditions 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Clinical Stage III Gastric Cancer AJCC v8 × Endoscopy × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡